gemcitabine teva 40mg/ml concentrate for solution for infusion
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - gemcitabine - concentrate for solution for infusion - gemcitabine - antineoplastic agents
gemcitabine teva 40 mg/ml concentrate for soln for inf
teva pharma b.v. - gemcitabine - concentrate for soln for inf - 40 mg/ml
gemcitabine teva 40 mg/ml, concentraat voor oplossing voor infusie
germist aerosol
mega-lab manufacturing co ltd - o-phenylphenol; p-tert-pentylphenol; alcohol anhydrous - aerosol - 0.10%; 0.03%; 53.72% - o-phenylphenol 0.10%; p-tert-pentylphenol 0.03%; alcohol anhydrous 53.72% - disinfectants (for agents used on object)
dafraclav 200/28 mg pediatric
dafra pharma gmbh - amoxicillin 200mg,clavulanic acid 28mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.
dafraclav 400/57 mg forte
dafra pharma gmbh - amoxicillin + clavulanic acid - amoxicillin 400mg,clavulanic acid 57mg - dafraclav is indicated in the treatment of the following infections caused by the microorganisms indicated below. - upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. - urinary tract infections. since dafraclav contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav, such an infection can be treated by the administration of dafraclav alone, addition of another antibiotic is not required.
dafraclav 625 mg film coated tablets
dafra pharma gmbh - tablets - amoxillin 500mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.
synovis supple peri-guard pericardium with apex processing
baxter healthcare (asia) pte ltd - cardiovascular - intended for repair of pericardial structures and for use as a prosthesis for the surgical repair of soft tissue deficiencies, which include: defects of the abdominal and thoracis wall, hernias (including diaphragmatic, femoral, incisional, inguinal, lumbar, paracolostomy, scrotal, and umbilical) and intracardiac and great vessel repair.
dressing, hydrogel
ferno australia pty ltd - 34082 - dressing, hydrogel - once applied, burnshields intended purpose is to protect against infection,minimise trauma and skin damage and to cool and soothe the effected area.
dressing, hydrogel
sentry medical pty ltd - 34082 - dressing, hydrogel - a sterile covering intended to cool and sooth burn site thus minimise skin damage and to protect it from infection and trauma.